Skip to content

Virtual Diabetes Group Visits Across Health Systems

VIDA: Virtual Diabetes Group Visits Across Health Systems: Randomized Control Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06094491
Acronym
VIDA
Enrollment
720
Registered
2023-10-23
Start date
2024-05-03
Completion date
2026-06-30
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease Chronic, Hyperlipidemias, Hypertension, Obesity, Peripheral Vascular Diseases, Stroke, T2DM (Type 2 Diabetes Mellitus)

Keywords

virtual group visits

Brief summary

The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).

Detailed description

Managing diabetes can be complex and burdensome; patients must modify their diet, take medications, check their blood sugar, and visit their healthcare providers regularly. Diabetes group visits (GVs)-virtual group education and diabetes support, including goal setting-create a unique setting where patients can connect with peers and receive medical care and support. GVs can improve glycemic control and decrease healthcare utilization. GVs can provide patients with comprehensive care for their multimorbid chronic condition. Virtual GVs provide an opportunity to adapt to the current trends of telehealth and the ability to increase reach and scalability across multiple sites. Before the model can be widely adopted, important questions about the effectiveness and implementation of the virtual diabetes GV model need to be addressed. The investigators propose to build on an established program of diabetes GVs. This proposal aims to implement the virtual GV model (VIDA: Virtual Diabetes Group Visits Across Health Systems) in two distinct health systems in the Chicago region. Access Community Health Network (ACCESS) is one of the largest federally qualified health centers (FQHCs) in the United States with 35 sites across the Chicago metropolitan area, providing care for 175,000 medically under-resourced and low-income patients each year. Advocate Health Care (ADVOCATE) is a large, integrated private not-for-profit health system that includes 26 hospitals and more than 500 ambulatory sites. The system provides care across more than 129 primary care clinics in Illinois serving over 117,000 patients. Both are community-based health systems serving low-income communities in Chicago and are network partners of the Chicago Chronic Conditions Engagement Network (C3EN). No studies have systematically implemented virtual diabetes GVs for adults with T2DM in the real-world primary care setting or across distinct health systems. The ability to train, implement, and evaluate virtual GVs across systems with different care models provides the opportunity to learn about adaptation and the obstacles and facilitators for implementation. This proposed study will compare virtual diabetes GVs to usual care using a type I hybrid effectiveness-implementation design via a pragmatic cluster randomized trial.

Interventions

BEHAVIORALVirtual Group Visit

Group visits must have these core components: diabetes education, group social support and goal setting.

Sponsors

University of Chicago
Lead SponsorOTHER
Wake Forest University Health Sciences
CollaboratorOTHER
ACCESS Community Health Network
CollaboratorOTHER
Midwest Clinicians' Network
CollaboratorUNKNOWN
National Institute on Minority Health and Health Disparities (NIMHD)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Type I hybrid effectiveness-implementation cluster randomized trial among adult patients with T2DM across 9 intervention sites and 9 control sites

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient at a PARTICIPATING clinic (at least one visit in year prior to first GV) * Type 2 diabetes * ≥ 18 years old * A1C\>8% within 6 months prior to first GV (we will first recruit patients with A1C\>9%, then if spaces still available A1C\>8.5%, then if spaces still available A1C\>8%) * At least one additional cardiovascular condition (hypertension, heart disease, stroke, hyperlipidemia, peripheral vascular disease, or BMI ≥ 30) * English or Spanish speaking * PCP assented to recruiting patient * Patient provides written consent

Design outcomes

Primary

MeasureTime frameDescription
A1c12 monthsThis is blood test that measures the percent of glucose and hemoglobin bound together.

Secondary

MeasureTime frameDescription
Systolic blood pressure12 monthsSystolic blood pressure measures the arterial pressure
Body Mass Index12 monthsMeasure of body fat based on height and weight
Low density lipoproteins12 monthsa measure of cholesterol in the blood

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORArshiya Baig, MD

University of Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026